The investigation of the TAAs specific immune response in tumor rejection

• Main Authors: Guo, Feng Shen, 郭峰伸
• Other Authors: Shen, Feng Wen
• Format: Others
• Language: zh-TW
• Published: 1995
• Online Access: http://ndltd.ncl.edu.tw/handle/83675953402538495240

碩士 === 國立臺灣大學 === 免疫學研究所 === 83 === Tumor associated antigens (TAAs) were defined as an unique antigen which were identified in tumor or benign cell but not in normal one. They could be recognized by T cells via the presen- tation of MHC molecules. There are many evidence to demonstrate that the CD8+ cytotoxic T lymphocyte (CTL) play an important ro- le in the process of tumor rejection. In addition, the expressi- on of MHC class I molecules on tumor cells is corelated to the ability of TAA presentation. Based on these concepts, we used RL ♂-1, a T cell leukemia cell line derived from BALB/c strain mo- use which was accepted by BALB/c mice but rejected by (BALB/c×B 6) F1 mouse, to study the relationship between TAAs and tumor r- ejection. It has been documented that pRL1 peptide was one of the TAAs in RL♂-1 which contained 8 amino acid and was restricted by H- 2Ld molecule. In the present expriments, we demonstrate the spe- cific T cell response could be induced in BALB/c mice after inj- ection of pRL1 peptide. It was then extended to establish the pR L1 specific T cell clones. The obtaintion of a specific CD8+ T cell lines have been sure through several restimulation in vitro and FACScan analysis, on the other word, the vaccination potent- ial of pRL1 peptide was examed. After heavy immunization, the t- umor was performed on unprimed BALB/c mice but was regressed ev- en rejected by peptide-primed BALB/c mice. In the future, the application of these CD8+ T ell lines and the vaccination effect of the pRL1 peptide should be improved f- rom the experimental design. And then, it will be expected to a- pply in the tumor immunology of human cancer therapy.